• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在大肠杆菌中产生的重组人白细胞介素-2的生物活性。

Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

作者信息

Rosenberg S A, Grimm E A, McGrogan M, Doyle M, Kawasaki E, Koths K, Mark D F

出版信息

Science. 1984 Mar 30;223(4643):1412-4. doi: 10.1126/science.6367046.

DOI:10.1126/science.6367046
PMID:6367046
Abstract

The gene for interleukin-2 was isolated from the Jurkat cell line and from normal peripheral blood lymphocytes and, when inserted in Escherichia coli, was expressed at high concentrations. This interleukin-2 was purified to apparent homogeneity and tested for biological activity in a variety of assays in vitro and in vivo. The recombinant lymphokine supports the growth of murine and human interleukin-2 dependent cell lines, enhances the generation of murine and human cytolytic cells in vitro, and generates lymphokine activated killer cells from murine and human lymphocytes. It has a serum half-life of 2 to 3 minutes in the mouse and significantly enhances the generation of cytolytic cells in vivo after alloimmunization. No functional differences between native and the recombinant interleukin-2 molecules have been detected.

摘要

白细胞介素-2基因是从Jurkat细胞系和正常外周血淋巴细胞中分离出来的,当插入大肠杆菌中时,能以高浓度表达。这种白细胞介素-2被纯化至明显的均一性,并在多种体外和体内试验中检测其生物活性。重组淋巴因子支持鼠和人白细胞介素-2依赖细胞系的生长,增强体外鼠和人溶细胞性细胞的生成,并从鼠和人淋巴细胞中产生淋巴因子激活的杀伤细胞。它在小鼠体内的血清半衰期为2至3分钟,在同种异体免疫后能显著增强体内溶细胞性细胞的生成。未检测到天然和重组白细胞介素-2分子之间的功能差异。

相似文献

1
Biological activity of recombinant human interleukin-2 produced in Escherichia coli.在大肠杆菌中产生的重组人白细胞介素-2的生物活性。
Science. 1984 Mar 30;223(4643):1412-4. doi: 10.1126/science.6367046.
2
Comparison of the biological properties of purified natural and recombinant human interleukin-2.纯化的天然和重组人白细胞介素-2生物学特性的比较。
Biochem Biophys Res Commun. 1985 Apr 16;128(1):257-64. doi: 10.1016/0006-291x(85)91672-9.
3
Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2.重组人白细胞介素-2(125)与天然白细胞介素-2的生物学活性比较。
J Biol Response Mod. 1985 Feb;4(1):96-109.
4
The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.淋巴因子激活的杀伤细胞和重组白细胞介素2在体内的抗肿瘤疗效:已形成转移灶的减少与淋巴因子激活的杀伤细胞的细胞溶解活性之间的直接相关性。
J Immunol. 1986 May 15;136(10):3899-909.
5
Expression of murine interleukin-2 cDNA in E. coli and biological activities of recombinant murine interleukin-2.小鼠白细胞介素-2 cDNA在大肠杆菌中的表达及重组小鼠白细胞介素-2的生物学活性
J Biochem. 1987 Oct;102(4):715-24. doi: 10.1093/oxfordjournals.jbchem.a122109.
6
Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients.重组白细胞介素-2对卵巢癌患者淋巴细胞的激活作用
Obstet Gynecol. 1989 May;73(5 Pt 1):793-7.
7
Induction of cytolytic cells by pure recombinant human interleukin 2.纯重组人白细胞介素2诱导溶细胞性细胞
Eur J Immunol. 1984 Nov;14(11):1057-60. doi: 10.1002/eji.1830141118.
8
In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.人白血病细胞在体外和体内对淋巴因子激活的杀伤活性的敏感性。
Leukemia. 1988 Jan;2(1):50-4.
9
Adherent lymphokine-activated natural killer cells in normal and severe combined immunodeficiency mice: large granular lymphocytes with natural killer cell phenotype and high cytolytic activity.正常和严重联合免疫缺陷小鼠中的黏附性淋巴因子激活的自然杀伤细胞:具有自然杀伤细胞表型和高细胞溶解活性的大颗粒淋巴细胞。
Nat Immun Cell Growth Regul. 1989;8(2):89-99.
10
Biological functions of recombinant human interleukin-2.重组人白细胞介素-2的生物学功能。
Chin J Biotechnol. 1991;7(1):25-31.

引用本文的文献

1
Jurkat T-cell lines exhibit marked genomic instability affecting karyotype, mutational profile, gene expression, immunophenotype and function.Jurkat T细胞系表现出明显的基因组不稳定,影响核型、突变谱、基因表达、免疫表型和功能。
Sci Rep. 2025 Jul 1;15(1):22426. doi: 10.1038/s41598-025-95903-0.
2
TIL Therapy in Lung Cancer: Current Progress and Perspectives.肺癌中的肿瘤浸润淋巴细胞疗法:当前进展与展望
Adv Sci (Weinh). 2024 Dec;11(46):e2409356. doi: 10.1002/advs.202409356. Epub 2024 Oct 18.
3
IL-2 based cancer immunotherapies: an evolving paradigm.
基于白细胞介素-2的癌症免疫疗法:一种不断演变的模式。
Front Immunol. 2024 Jul 24;15:1433989. doi: 10.3389/fimmu.2024.1433989. eCollection 2024.
4
Lifileucel: FDA-approved T-cell therapy for melanoma.利弗利塞(Lifileucel):FDA 批准的用于黑色素瘤的 T 细胞疗法。
Oncologist. 2024 Aug 5;29(8):648-650. doi: 10.1093/oncolo/oyae136.
5
Modern therapies of nonsmall cell lung cancer.非小细胞肺癌的现代疗法。
J Appl Genet. 2023 Dec;64(4):695-711. doi: 10.1007/s13353-023-00786-4. Epub 2023 Sep 12.
6
Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.免疫检查点抑制剂和 IL2 反应的预测性免疫基因组特征:晚期肾癌患者的真实世界证据研究。
Cancer Res Commun. 2022 Aug 30;2(8):894-903. doi: 10.1158/2767-9764.CRC-21-0153. eCollection 2022 Aug.
7
Highlights into historical and current immune interventions for cancer.癌症免疫治疗的历史和现状概述。
Int Immunopharmacol. 2023 Apr;117:109882. doi: 10.1016/j.intimp.2023.109882. Epub 2023 Feb 27.
8
Immersion in the search for effective cancer immunotherapies.全身心投入寻找有效的癌症免疫疗法。
Mol Med. 2021 Jun 16;27(1):63. doi: 10.1186/s10020-021-00321-3.
9
Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.肿瘤急症:基于免疫的癌症治疗及其并发症。
West J Emerg Med. 2020 Apr 13;21(3):566-580. doi: 10.5811/westjem.2020.1.45898.
10
The Intriguing History of Cancer Immunotherapy.癌症免疫疗法的迷人历史。
Front Immunol. 2019 Dec 17;10:2965. doi: 10.3389/fimmu.2019.02965. eCollection 2019.